Akston Biosciences Awarded Phase II SBIR by NIH/NIDDK
Akston Biosciences received notice that it has been awarded $998,998 in second year funding for a Phase II SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). The grant was awarded to support IND-enabling manufacturing development, as well as toxicology and safety pharmacology studies of AKS-107, the company’s lead candidate for the prevention of Type 1 Diabetes.